About 14 results found for searched term "LL-K8-22" (0.124 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M41422 | LL-K8-22 | CDK |
| LL-K8-22 is a potent, selective and durable CDK8-cyclin C dual degrader, with DC50 values of 2.52 and 2.64 μM, respectively. | ||
| M5303 | 1-Naphthyl PP1 | PKC |
| 1-NA-PP 1 | ||
| 1-Naphthyl PP1(1-NA-PP 1) is a selective inhibitor of src family kinases v-Src and c-Fyn as well as the tyrosine kinase c-Abl (IC50 values are 1.0, 0.6, 0.6, 18 and 22 μM for v-Src, c-Fyn, c-Abl, CDK2 and CAMK II respectively). | ||
| M9746 | CU-CPT-8m | TLR |
| CU-CPT8m; TLR8-specific antagonist | ||
| CU-CPT8m is an antagonist of toll-like receptor 8 (TLR8) with Kd of 220 nM and IC50 of 67 nM in assay. | ||
| M10848 | LP-922761 | Others |
| LP-922761 is a potent, selective, orally active AAK1 inhibitor in enzymatic and cell analysis IC50 4.8 nM and 7.6 nM, respectively. LP-922761 also inhibits BMP-2-induced protein kinase (BIKE),IC50 24 nM. LP-922761 has no significant activity against cell GAK, opioids, epinephrine alpha2, or GABAa receptors. | ||
| M21429 | Recombinant Human SDF-1β/CXCL12 (E. coli) | Cytokines and Growth Factors |
| SDF1β; SDF-1 beta; CXCL-12 | ||
| Stromal cell-derived factor-1β (SDF-1β), also known as SCYB12, PBSF, and CXCL12, is an 8.3 kDa, heparin-bound member of the CXC(or α) chemokine family that signals via the CXCR4 receptor. Protein Construction: SDF-1β/CXCL12 (Lys22-Met93). Accession # P48061. | ||
| M28107 | PF-3644022 | MAPKAPK2/MAP3K/MAP4K |
| PF-3644022 is a potent, selective, orally active and ATP-competitive MAPKAPK2 (MK2) inhibitor with an IC50 of 5.2 nM and a Ki of 3 nM. PF-3644022 also inhibits MK3 and p38 regulated/activated kinase (PRAK) with IC50s of 53 nM and 5.0 nM, respectively. PF-3644022 potently inhibits TNFα production and has anti-inflammatory effect. | ||
| M28536 | Risovalisib | PI3K |
| CYH33 | ||
| Risovalisib (CYH33) is an orally active, highly selective PI3Kα inhibitor with IC50s of 5.9 nM/598 nM/78.7 nM/225 nM against α/β/δ/γ isoform, respectively. Risovalisib inhibits phosphorylation of Akt, ERK and induces significant G1 phase arrest in breast cancer cells and non-small cell lung cancer (NSCLC) cells. Risovalisib has potent activity against solid tumors. | ||
| M28537 | CYH33 methanesulfonate | PI3K |
| CYH33 methanesulfonate is an orally active, highly selective PI3Kα inhibitor with IC50s of 5.9 nM/598 nM/78.7 nM/225 nM against α/β/δ/γ isoform, respectively. CYH33 methanesulfonate inhibits phosphorylation of Akt, ERK and induces significant G1 phase arrest in breast cancer cells and non-small cell lung cancer (NSCLC) cells. CYH33 methanesulfonate has potent activity against solid tumors. | ||
| M28596 | GNE-9822 | Itk |
| GNE-9822 is a potent, orally active and selective ITK inhibitor with a Ki value of 0.7 nM. GNE-9822 has good ADME properties. GNE-9822 can be used in research of asthma. | ||
| M28792 | SD-169 | p38 MAPK |
| SD-169 is an orally active ATP-competitive inhibitor of p38α MAPK, with an IC50 of 3.2 nM. SD-169 also weakly inhibits p38β MAPK with an IC50 of 122 nM. SD-169 prevents the development and progression of diabetes by inhibiting T cell infiltration and activation. | ||
| M29121 | JNJ-56022486 | GluR |
| JNJ-56022486 is an orally active and potent negative AMPA receptor modulator (Ki=19 nM) selective for TARP-γ8. JNJ-56022486 is also a TARP-γ8 receptor antagonist, with blood brain barrier (BBB) permeability. JNJ-56022486 can be used for research of Epilepsy. | ||
| M29139 | BMS-986224 | Others |
| BMS-986224 is a potent, selective and orally active APJ receptor agonist (Kd = 0.3 nM). BMS-986224 exhibits similar receptor binding and signaling profile to (Pyr1) apelin-13. BMS-986224 has the potential for the research of heart failure. | ||
| M29174 | CHMFL-ABL/KIT-155 | Src-bcr-Abl |
| CHMFL-ABL-KIT-155 | ||
| CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155; compound 34) is a highly potent and orally active type II ABL/c-KIT dual kinase inhibitor (IC50s of 46 nM and 75 nM, respectively), and it also presents significant inhibitory activities to BLK (IC50=81 nM), CSF1R (IC50=227 nM), DDR1 (IC50=116 nM), DDR2 (IC50=325 nM), LCK (IC50=12 nM) and PDGFRβ (IC50=80 nM) kinases. | ||
| M30587 | Emprumapimod | p38 MAPK |
| PF-07265803 | ||
| Emprumapimod (PF-07265803) is a potent, orally active and selective inhibitor of p38α MAPK directly inhibits LPS-induced IL-6 production from RPMI-8226 cell (IC50=100 pM). Emprumapimod can be used for the research of dilated cardiomyopathy and acute inflammatory pain. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
